Open AccessPharmacokinetics of an Increased Atazanavir Dose With and Without Tenofovir During the Third Trimester of Pregnancy
Author(s) -
Régis Kreitchmann,
Brookie M. Best,
Jiajia Wang,
Alice Stek,
Edmund Caparelli,
D. Heather Watts,
Elizabeth Smith,
David E. Shapiro,
Steve S. Rossi,
Sandra Burchett,
Elizabeth Hawkins,
Mark Byroads,
Tim R. Cressey,
Mark Mirochnick
Publication year - 2013
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0b013e318289b4d2
Subject(s) - atazanavir , pharmacokinetics , ritonavir , medicine , dosing , trough concentration , lopinavir , pregnancy , pharmacology , human immunodeficiency virus (hiv) , viral load , antiretroviral therapy , virology , biology , genetics
Reduced atazanavir exposure has been demonstrated during pregnancy with standard atazanavir/ritonavir dosing. We studied an increased dose during the third trimester of pregnancy.